The European Confederation of Medical Mycology (ECMM) has conducted an observational study to determine the rate of occurrence of invasive mould disease (IMD) and treatment outcomes in at-risk patients. It is the first study of its kind in IMD.
European hospitals with haematology units and/or transplant centres that frequently treat patients for AML/MDS, or recipients of an allogeneic HSCT, or both, have participated. 1243 patients were recruited, of which 1205 were considered suitable for inclusion in the analysis.”
This ECMM study is supported by an independent investigator research grant from Pfizer.
Download the PIMDA ePoster